Gilead calls dibs on a PhI bis­pe­cif­ic, hands over $60M to cash-strapped Macro­Gen­ics

On a con­tin­u­al search for more bas­kets to put its on­col­o­gy eggs in, Gilead has land­ed on a hot tar­get: CD123.

Specif­i­cal­ly, Gilead is grab­bing a bis­pe­cif­ic an­ti­body from Macro­Gen­ics, a sea­soned biotech play­er that’s seen its share of set­backs. For $60 mil­lion up­front, Gilead buys an ex­clu­sive op­tion to li­cense MGD024 af­ter Macro­Gen­ics wraps up the on­go­ing Phase I study and calls dibs on two oth­er ear­ly-stage bis­pe­cif­ic re­search pro­grams.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER